Krystal Biotech Q4 2025 product revenue $107.1M; net income $51.4M; regulatory wins for KB707, KB111

Krystal Biotech, Inc.

2025-FY EPS reported $6.84 revenue$389,130,000

Q4 product revenue $107.1M (up from $91.1M YoY); FY revenue $389.1M; net income $204.8M ($7.08 basic EPS) vs $89.2M prior year.
FDA granted RMAT designation to KB707 for advanced NSCLC and Fast Track to KB111 for Hailey-Hailey disease.
Positive CORAL-1 CF data: inhaled KB407 achieved 29.4%-42.1% airway cell transduction; CORAL-3 enrollment expected 1H 2026.
Cash and investments $955.9M; FY 2026 non-GAAP R&D+SG&A guidance $175-195M.
VYJUVEK has over 660 US reimbursement approvals; launched in Germany, France, Japan; Israel agreement signed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.